Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence.

摘要: Background This study aimed to analyze timing and sites of recurrence for patients receiving neoadjuvant chemotherapy gastric cancer. Neoadjuvant followed by surgical resection is the standard treatment locally advanced cancer in West, but limited information exists as patterns this setting. Methods Patients with clinical stage 2 or 3 treated curative-intent between January 2000 December 2015 were analyzed 5-year recurrence-free survival (RFS) well site recurrence. Results Among 312 identified patients, 121 (38.8%) experienced during a median follow-up period 46 months. The overall RFS rate was 58.9%, rates 95.8% ypT0N0, 81% ypStage 1, 77.4% 2, 22.9% 3. first peritoneal 49.6%, distant (not peritoneal) 45.5%, locoregional 11.6% patients. majority recurrences (84.3%) occurred within years. Multivariate analysis showed that ypT4 status an independent predictor 1 year after surgery (odds ratio, 2.58; 95% confidence interval, 1.10-6.08; p = 0.030). Conclusions who received underwent curative After chemotherapy, pathologic T useful risk early